Evaluating SARS-CoV-2 Seroconversion Following Relieve of Confinement Measures
Seroprevalence studies are crucial both for estimating the prevalence of SARS-CoV-2 exposure and to provide a measure for the efficiency of the confinement measures. Portuguese universities were closed on March 16th 2020, when Portugal only registered 62 SARS-CoV-2 infection cases per million. We ha...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-12-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2020.603996/full |
| _version_ | 1818591760717185024 |
|---|---|
| author | Juliana Gonçalves Juliana Gonçalves Rita L. Sousa Rita L. Sousa Maria J. Jacinto Daniela A. Silva Daniela A. Silva Filipe Paula Filipe Paula Filipe Paula Rute Sousa Rute Sousa Sara Zahedi Sara Zahedi Joana Carvalho Joana Carvalho M. Guadalupe Cabral M. Guadalupe Cabral Manuela Costa Jaime C. Branco Jaime C. Branco Helena Canhão Helena Canhão José D. Alves José D. Alves José D. Alves Ana M. Rodrigues Ana M. Rodrigues Helena Soares Helena Soares |
| author_facet | Juliana Gonçalves Juliana Gonçalves Rita L. Sousa Rita L. Sousa Maria J. Jacinto Daniela A. Silva Daniela A. Silva Filipe Paula Filipe Paula Filipe Paula Rute Sousa Rute Sousa Sara Zahedi Sara Zahedi Joana Carvalho Joana Carvalho M. Guadalupe Cabral M. Guadalupe Cabral Manuela Costa Jaime C. Branco Jaime C. Branco Helena Canhão Helena Canhão José D. Alves José D. Alves José D. Alves Ana M. Rodrigues Ana M. Rodrigues Helena Soares Helena Soares |
| author_sort | Juliana Gonçalves |
| collection | DOAJ |
| description | Seroprevalence studies are crucial both for estimating the prevalence of SARS-CoV-2 exposure and to provide a measure for the efficiency of the confinement measures. Portuguese universities were closed on March 16th 2020, when Portugal only registered 62 SARS-CoV-2 infection cases per million. We have validated a SARS-CoV-2 ELISA assay to a stabilized full-length spike protein using 216 pre-pandemic and 19 molecularly diagnosed SARS-CoV-2 positive individual's samples. At NOVA University of Lisbon, presential work was partially resumed on May 25th with staggered schedules. From June 15th to 30th, 3–4 weeks after the easing of confinement measures, we screened 1,636 collaborators of NOVA university of Lisbon for the presence of SARS-CoV-2 spike specific IgA and IgG antibodies. We found that spike-specific IgG in 50 of 1,636 participants (3.0%), none of which had anti-spike IgA antibodies. As participants self-reported as asymptomatic or paucisymptomatic, our study also provides a measurement of the prevalence of asymptomatic/paucisymptomatic SARS-CoV-2 infections. Our study suggests that essential workers have a 2-fold increase in viral exposure, when compared to non-essential workers that observed confinement. Additional serological surveys in different population subgroups will paint a broader picture of the effect of the confinement measures in the broader community. |
| first_indexed | 2024-12-16T10:17:34Z |
| format | Article |
| id | doaj.art-cb393323465f40a8a97f31a5f9cee2b2 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-12-16T10:17:34Z |
| publishDate | 2020-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-cb393323465f40a8a97f31a5f9cee2b22022-12-21T22:35:24ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2020-12-01710.3389/fmed.2020.603996603996Evaluating SARS-CoV-2 Seroconversion Following Relieve of Confinement MeasuresJuliana Gonçalves0Juliana Gonçalves1Rita L. Sousa2Rita L. Sousa3Maria J. Jacinto4Daniela A. Silva5Daniela A. Silva6Filipe Paula7Filipe Paula8Filipe Paula9Rute Sousa10Rute Sousa11Sara Zahedi12Sara Zahedi13Joana Carvalho14Joana Carvalho15M. Guadalupe Cabral16M. Guadalupe Cabral17Manuela Costa18Jaime C. Branco19Jaime C. Branco20Helena Canhão21Helena Canhão22José D. Alves23José D. Alves24José D. Alves25Ana M. Rodrigues26Ana M. Rodrigues27Helena Soares28Helena Soares29Human Immunobiology and Pathogenesis Laboratory, Lisbon, PortugalCEDOC-Chronic Diseases Research Center, NOVA Medical School | Faculdade de Ciências Médicas, NOVA University of Lisbon, Lisbon, PortugalHuman Immunobiology and Pathogenesis Laboratory, Lisbon, PortugalCEDOC-Chronic Diseases Research Center, NOVA Medical School | Faculdade de Ciências Médicas, NOVA University of Lisbon, Lisbon, PortugalCatólica-Lisbon School of Business and Economics, Catholic University of Portugal, Lisbon, PortugalHuman Immunobiology and Pathogenesis Laboratory, Lisbon, PortugalCEDOC-Chronic Diseases Research Center, NOVA Medical School | Faculdade de Ciências Médicas, NOVA University of Lisbon, Lisbon, PortugalCEDOC-Chronic Diseases Research Center, NOVA Medical School | Faculdade de Ciências Médicas, NOVA University of Lisbon, Lisbon, PortugalInternal Medicine Department IV/Immune Mediated Systemic Diseases (UDIMS), Fernando Fonseca Hospital, Amadora, PortugalImmune Response and Vascular Disease Laboratory, Lisbon, PortugalComprehensive Health Research Center (CHRC), NOVA Medical School, Lisbon, PortugalEpiDoC Unit, CEDOC, NOVA Medical School, UNL, Lisbon, PortugalCEDOC-Chronic Diseases Research Center, NOVA Medical School | Faculdade de Ciências Médicas, NOVA University of Lisbon, Lisbon, PortugalComputational and Experimental Biology Laboratory, Lisbon, PortugalInternal Medicine Department IV/Immune Mediated Systemic Diseases (UDIMS), Fernando Fonseca Hospital, Amadora, PortugalImmune Response and Vascular Disease Laboratory, Lisbon, PortugalCEDOC-Chronic Diseases Research Center, NOVA Medical School | Faculdade de Ciências Médicas, NOVA University of Lisbon, Lisbon, PortugalTissue Repair and Inflammation Laboratory, Lisbon, Portugal0Rheumatology Department, CHLO, Egas Moniz Hospital, Lisbon, PortugalComprehensive Health Research Center (CHRC), NOVA Medical School, Lisbon, Portugal0Rheumatology Department, CHLO, Egas Moniz Hospital, Lisbon, PortugalComprehensive Health Research Center (CHRC), NOVA Medical School, Lisbon, PortugalEpiDoC Unit, CEDOC, NOVA Medical School, UNL, Lisbon, PortugalCEDOC-Chronic Diseases Research Center, NOVA Medical School | Faculdade de Ciências Médicas, NOVA University of Lisbon, Lisbon, PortugalInternal Medicine Department IV/Immune Mediated Systemic Diseases (UDIMS), Fernando Fonseca Hospital, Amadora, PortugalImmune Response and Vascular Disease Laboratory, Lisbon, PortugalComprehensive Health Research Center (CHRC), NOVA Medical School, Lisbon, PortugalEpiDoC Unit, CEDOC, NOVA Medical School, UNL, Lisbon, PortugalHuman Immunobiology and Pathogenesis Laboratory, Lisbon, PortugalCEDOC-Chronic Diseases Research Center, NOVA Medical School | Faculdade de Ciências Médicas, NOVA University of Lisbon, Lisbon, PortugalSeroprevalence studies are crucial both for estimating the prevalence of SARS-CoV-2 exposure and to provide a measure for the efficiency of the confinement measures. Portuguese universities were closed on March 16th 2020, when Portugal only registered 62 SARS-CoV-2 infection cases per million. We have validated a SARS-CoV-2 ELISA assay to a stabilized full-length spike protein using 216 pre-pandemic and 19 molecularly diagnosed SARS-CoV-2 positive individual's samples. At NOVA University of Lisbon, presential work was partially resumed on May 25th with staggered schedules. From June 15th to 30th, 3–4 weeks after the easing of confinement measures, we screened 1,636 collaborators of NOVA university of Lisbon for the presence of SARS-CoV-2 spike specific IgA and IgG antibodies. We found that spike-specific IgG in 50 of 1,636 participants (3.0%), none of which had anti-spike IgA antibodies. As participants self-reported as asymptomatic or paucisymptomatic, our study also provides a measurement of the prevalence of asymptomatic/paucisymptomatic SARS-CoV-2 infections. Our study suggests that essential workers have a 2-fold increase in viral exposure, when compared to non-essential workers that observed confinement. Additional serological surveys in different population subgroups will paint a broader picture of the effect of the confinement measures in the broader community.https://www.frontiersin.org/articles/10.3389/fmed.2020.603996/fullSARS-CoV2serosurveyIgA and IgGpauci/asymptomatic COVID-19 prevalencepost-confinement community setting |
| spellingShingle | Juliana Gonçalves Juliana Gonçalves Rita L. Sousa Rita L. Sousa Maria J. Jacinto Daniela A. Silva Daniela A. Silva Filipe Paula Filipe Paula Filipe Paula Rute Sousa Rute Sousa Sara Zahedi Sara Zahedi Joana Carvalho Joana Carvalho M. Guadalupe Cabral M. Guadalupe Cabral Manuela Costa Jaime C. Branco Jaime C. Branco Helena Canhão Helena Canhão José D. Alves José D. Alves José D. Alves Ana M. Rodrigues Ana M. Rodrigues Helena Soares Helena Soares Evaluating SARS-CoV-2 Seroconversion Following Relieve of Confinement Measures Frontiers in Medicine SARS-CoV2 serosurvey IgA and IgG pauci/asymptomatic COVID-19 prevalence post-confinement community setting |
| title | Evaluating SARS-CoV-2 Seroconversion Following Relieve of Confinement Measures |
| title_full | Evaluating SARS-CoV-2 Seroconversion Following Relieve of Confinement Measures |
| title_fullStr | Evaluating SARS-CoV-2 Seroconversion Following Relieve of Confinement Measures |
| title_full_unstemmed | Evaluating SARS-CoV-2 Seroconversion Following Relieve of Confinement Measures |
| title_short | Evaluating SARS-CoV-2 Seroconversion Following Relieve of Confinement Measures |
| title_sort | evaluating sars cov 2 seroconversion following relieve of confinement measures |
| topic | SARS-CoV2 serosurvey IgA and IgG pauci/asymptomatic COVID-19 prevalence post-confinement community setting |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2020.603996/full |
| work_keys_str_mv | AT julianagoncalves evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT julianagoncalves evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT ritalsousa evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT ritalsousa evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT mariajjacinto evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT danielaasilva evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT danielaasilva evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT filipepaula evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT filipepaula evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT filipepaula evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT rutesousa evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT rutesousa evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT sarazahedi evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT sarazahedi evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT joanacarvalho evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT joanacarvalho evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT mguadalupecabral evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT mguadalupecabral evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT manuelacosta evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT jaimecbranco evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT jaimecbranco evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT helenacanhao evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT helenacanhao evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT josedalves evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT josedalves evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT josedalves evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT anamrodrigues evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT anamrodrigues evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT helenasoares evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures AT helenasoares evaluatingsarscov2seroconversionfollowingrelieveofconfinementmeasures |